arsenic has been researched along with Graft vs Host Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batteux, F; Chéreau, C; Kavian, N; Laude, H; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Ackerstein, A; Bitan, M; Gesundheit, B; Or, R; Resnik, IB; Shapira, MY | 1 |
2 other study(ies) available for arsenic and Graft vs Host Disease
| Article | Year |
|---|---|
Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Chronic Disease; Disease Models, Animal; Female; Fibrosis; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxides; Random Allocation; Scleroderma, Systemic; Spleen | 2012 |
A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Oxides | 2007 |